Tenet Healthcare Corp’s recently made public that its Director Romo Tammy acquired Company’s shares for reported $3.03 million on Nov 03 ’25. In the deal valued at $200.80 per share,15,099 shares were bought.
Then, FISHER RICHARD W sold 2,500 shares, generating $521,075 in total proceeds. Upon selling the shares at $208.43, the Director now owns 8,792 shares.
Before that, FISHER RICHARD W bought 2,500 shares. Tenet Healthcare Corp shares valued at $521,075 were divested by the Director at a price of $208.43 per share.
A number of analysts have revised their coverage, including Wolfe Research’s analysts, who decreased its forecast for the stock in late July from “an Outperform” to “a Peer perform”. Wells Fargo also remained covering THC and has increased its forecast on May 29, 2025 with a “an Overweight” recommendation from previously “an Equal weight” rating. Robert W. Baird revised its rating on April 15, 2025. It rated THC as “a Neutral” which previously was an “an Outperform”.
Price Performance Review of THC
On Monday, Tenet Healthcare Corp [NYSE:THC] saw its stock fall -2.47% to $201.39. Over the last five days, the stock has lost -6.84%. Tenet Healthcare Corp shares have risen nearly 27.40% since the year began. Nevertheless, the stocks have risen 59.54% over the past one year. While a 52-week high of $217.43 was reached on 10/24/25, a 52-week low of $109.82 was recorded on 04/21/25.
Levels Of Support And Resistance For THC Stock
The 24-hour chart illustrates a support level at 197.89, which if violated will result in even more drops to 194.38. On the upside, there is a resistance level at 205.34. A further resistance level may holdings at 209.28.
How much short interest is there in Tenet Healthcare Corp?
A steep rise in short interest was recorded in Tenet Healthcare Corp stocks on 2025-10-15, growing by 28482.0 shares to a total of 2.55 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-15 was 2.52 million shares. There was a rise of 1.12%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 26, 2025 when Morgan Stanley began covering the stock and recommended ‘”an Overweight”‘ rating along with a $165 price target.
